Kornimate/medical-research-clean huggingface dataset:
investigation of the effectiveness of antioxidant therapy in oligoasthenoteratozoospermic infertile men

Conditions: Male Infertility

Summary: approximately 30% of the factors that cause male infertility are due to idiopathic causes. increased reactive oxygen species (ros) due to many known and unknown factors cause male infertility by affecting spermatogenesis and sperm maturation. in this study, the effects of physical activity and antioxidant food supplementation on seminal antioxidant capacity, sperm dna fragmentation index, sperm chromatin quality and sperm parameters were investigated in infertile cases.

material and method: the study included subfertile men with idiopathic oligoasthenoteratozospermia seen at ondokuz mayıs university faculty of medicine between march 2021 and november 2021. all subjects were recommended to do moderate physical activity for at least 45 minutes (at least 150 minutes-600 mets per week) 3-4 days a week for three months. a total of 48 cases were divided into two groups by computer-assisted (www.randomizer.org) complete (simple) randomization. in the first group (group 1), 2000 mg l-carnitine, 2000 mg fructose, 932 mg acetyl l-carnitine, 225 mg vitamin c, 115 mg citric acid, 50 mg coenzyme q10, 14 mg zinc, 115 µg selenium, 3750 µg food supplement containing vitamin b12 and 500 µg folic acid was recommended as one sachet in the morning and evening, while antioxidant food supplement was not given to the second group (group 2). before and after treatment, semen parameters, hormone analyzes with elisa method, physical activity evaluation with ipaq questionnaire, seminal antioxidant capacity with trolox equivalent antioxidant capacity (teac) measurement method, dna fragmentation index with tunel method. and sperm chromatin structure was evaluated by aniline blue staining. student's t test was used for the variables showing normal distribution in independent groups, and mann whitney u test was used for the variables that did not fit the normal distribution. paired t test was used for the variables showing normal distribution in the dependent groups, and wilcoxon test was used for the variables that were found not to fit the normal distribution.

Eligibility criteria:
inclusion criteria: 1) clinical diagnosis of idiopathic oligoasthenoteratozoospermia - exclusion criteria: 1. vasectomy 2. azoospermia or severe oligozoospermia 3. current use of a treatment or drug 4. cancer, heart disease or cirrhosis history 5. uncontrolled diabetes mellitus -

Keywords: exercise antioxidant antioxidant capacity sperm dna fragmentation protamine
omadacycline vs moxifloxacin for the treatment of cabp (eudract #2013-004071-13)

Conditions: Bacterial Pneumonia; Community-Acquired Infections

Summary: the purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.


Eligibility criteria:
inclusion criteria: * patients, ages 18 years or older who have signed the informed consent * has qualifying bacterial pneumonia * female patients must not be pregnant at the time of enrollment * must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug exclusion criteria: * known or suspected hospital-acquired pneumonia * evidence of significant immunological disease * has a history of hypersensitivity or allergic reaction to any tetracycline or to any fluoroquinolone antibiotic * has received an investigational drug within past 30 days * women who are pregnant or nursing
rapid diagnosis of patients with chest pain during the covid-19 outbreak (my-abcde)

Conditions: Chest Pain

Summary: during the outbreak of covid-19, among patients with chest tightness and chest pain as the main symptoms in major medical institutions in shanghai, china, the past medical history and rapid testing were used to quickly identify the risk stratification of the patients.

during the outbreak of covid-19, among patients with chest tightness and chest pain as the main symptoms in major medical institutions in shanghai, china, the past medical history and rapid testing were used to quickly identify the risk stratification of the patients. past medical history collection includes diabetes, hypertension, coronary atherosclerotic heart disease, percutaneous coronary stent implantation, etc. rapid detection includes rapid myocardial markers, coagulation function, electrocardiogram, chest ct, etc. risk stratification in the shortest possible time to reduce the time patients spend congregating in hospitals and reduce unnecessary contact to reduce the risk of covid-19 infection.

Eligibility criteria:
inclusion criteria: * all patients who came to the hospital with chest tightness and chest pain during covid-19. exclusion criteria: * none.
enhancing hair density with platelet rich fibrin matrix (prfm)

Conditions: Alopecia

Summary: clinical alopecia occurs due to miniaturization of the hair shafts as well as loss of active production of hair shafts. prfm has been shown to induce dermal angiogenesis, and anecdotal findings of improvement of hair appearance after prfm injection in the scalp suggest that prfm may play a role in the treatment of thinning hair. patients will be treated on a monthly basis with intradermal injections of autologous prfm for 3 months. changes in hair density will be assessed by comparing pre- and post-treatment photographs and non-invasive measurements of hair density at 1, 2, 3, 4 and 6 months after initial treatment.


Eligibility criteria:
inclusion criteria: * age 18- 75 years old * frontal and/or crown alopecia exclusion criteria: * bleeding disorder

Keywords: alopecia
comparative impact of rast and tst for improving motor functions in stroke patients

Conditions: Stroke

Summary: this study evaluates the effectiveness of rhythmic auditory stimulation (ras) therapy versus task-specific training (tst) in enhancing motor function recovery in stroke patients. ras uses rhythmic cues to aid movement synchronization, while tst focuses on practicing daily tasks to improve functional ability. in a randomized clinical trial, participants were assigned to either ras or tst groups, with both receiving structured sessions over several weeks.


Eligibility criteria:
inclusion criteria: * male and female patients diagnosed with stroke * age 40-80 years (46) * patients having first ever stroke occurrence * moderate motor function impairments (47) * patients able to follow instruction exclusion criteria: * patients with severe motor impairments * patients who had cognitive impairments * patients having other neurological conditions and musculoskeletal disorders * patients having history of surgery
a study of jnj-88998377 for relapsed/refractory b-cell non-hodgkin's lymphoma

Conditions: Lymphoma, Non-Hodgkin; Refractory B-Cell NHL; Relapsed B-cell NHL

Summary: the main purpose of this study is to characterize safety and to determine the recommended phase 2 dose (rp2d) for jnj-88998377 (part a: dose escalation) and to further assess the safety of jnj-88998377 at the rp2d (part b: dose expansion).


Eligibility criteria:
inclusion criteria: * participants have histologically or cytologically confirmed b-cell non-hodgkin's lymphoma (nhl) according to the 2022 world health organization (who) classification with relapsed or refractory disease * participants have measurable disease or meet all requirements for adequate response assessment as defined by the appropriate disease response criteria at screening * participants have an eastern cooperative oncology group (ecog) performance status of 0 or 1 * participants have a life expectancy of greater than or equal to (\>=) 12 weeks * be willing and able to adhere to the lifestyle restrictions specified in the protocol exclusion criteria: * participant with active or prior history of b-cell nhl involving the central nervous system (cns) and leptomeningeal involvement * history of malignancy (other than the disease under study in the cohort to which the participant is assigned) within 1 year prior to the first administration of study treatment as malignancies can interfere with study endpoints * participant having known allergies, hypersensitivity, or intolerance to the excipients of jnj-88998377 * participant had major surgery or had significant traumatic injury within 30 days before first dose of study treatment or has not recovered from surgery and must not have major surgery planned during the time the participant is receiving study treatment * participant received an autologous stem cell transplant less than or equal to (\<=) 3 months before the first dose of study treatment
validation of near-infrared light transillumination for interproximal enamel caries detection

Conditions: Dental Caries

Summary: the aim of this study is to validate a near-infrared light transillumination device (diagnocam, kavo, biberach, germany) for interproximal enamel caries detection and compare it with the established diagnostic methods (visual examination and bitewing radiography). the aim is to avoid/reduce ionizing radiation for caries diagnostic purposes.


Eligibility criteria:
inclusion criteria: * asa-status 1 * complete permanent dentition * bitewing radiography already existing (\< 4 months) * minimum of one cavitation-free approximal surface, symptomless, interproximal enamel or dentin caries lesion in the posterior teeth without restorations and/or sound tooth surface. exclusion criteria: * children younger than 15 years

Keywords: interproximal caries enamel caries caries detection caries diagnostics near-infrared light transillumination diagnocam
efficacy of matricariae chamomilla l., melissa officinalis l. and tyndallized lactobacillus acidophilus (h122) for infantile colics

Conditions: Infantile Colics

Summary: a multicenter prospective, randomized comparative study will be conducted in infants with colic, according to rome iii criteria. enrolled infants will be assigned at random to receive chamomilla l., melissa officinalis l. and tyndallized l. acidophilus (h122), l reuteri dsm 17938 (108 cfu) or simethicone. treatment will be given to subjects for 28 days and they will be followed for 4 weeks. treatment success will be assessed at the end of study period. daily crying and fussing times will be recorded in a structured diary, and maternal questionnaires will be completed to monitor changes in infant colic symptoms and adverse events.

this will be a prospective, multicentre, open label, randomized, controlled trial. all consecutive infants diagnosed with ic, according to rome iii criteria, will be prospectively enrolled in a 12 months period by 3 different pediatric gastroenterology units: department of translational medical science, section of pediatrics, university of naples "federico ii"; institute of pediatrics of the university of foggia; endoscopy and gastroenterology unit, department of pediatrics, university of messina. after the enrollment, all children will be randomly assigned to receive chamomilla l., melissa officinalis l. and tyndallized l. acidophilus (h122) (group a), l reuteri dsm 17938 (108 cfu) (group b) or simethicone (group c). treatment will be given to subjects for 28 days. the study's primary outcome is defined as a reduction in the duration of average crying times, from baseline (day 0) to end of treatment (day 28). the secondary outcome measure is the number of participants who respond to treatment on days 28. infants who experience a decrease in the daily average crying time of 50% from baseline will be considered as responders to the treatment. parents will be instructed to complete a structured 28-day maternal diary, modified from barr et al. in order to record the frequency of colic episodes and the daily crying and fussing time (in minutes), feeding schedule, stool frequency and characteristics, and any adverse events experienced (14). follow-up visits will be conducted on study days 7, 14, 21 and 28 by the same study investigator. at that visit, diaries and unused study products will be returned.

Eligibility criteria:
inclusion criteria: 1. diagnosis of ic according to rome iii criteria (2); 2. age ≥2 weeks to 4 months; 3. breast-fed or fomula-fed infants; 4. term delivery (≥37 weeks gestation at birth); 5. 5-minute apgar score ≥7; and 6) birth weight ≥2500 g exclusion criteria: 1. a major medical problem or acute illness; 2. family history of atopy; 3. history of antibiotic treatment before or during the study; 4. history of probiotic supplementation.

Keywords: infantile colics
genome-wide pharmacogenetic candidate gene single nucleotide polymorphism (snp) array-based approach to predict chemoresponse and survival in patients with acute myeloid leukemia with normal karyotype

Conditions: Myeloid Leukemia

Summary: the most reliable prognostic marker of acute myeloid leukemia(aml) is cytogenetics by karyotyping. according to cytogenetic results, the patients with aml are classified as better, intermediate and poor prognosis groups. the normal karyotype aml was reported in about 50% of all aml and classified as intermediate risk group. however, the patients with normal karyotype aml showed various prognosis. therefore, the further studies about subgroup analysis of normal karyotype aml are needed. recently, the understandings of human genome polypmorphism using snp array have been accumulated. however, the advanced researches for clinical application are not enough. the study design is a retrospective and single-center study. the patients with normal karyotyping aml who were diagnosed from 1994 to 2008 at samsung medical center (south korea) will be enrolled. the stored bone marrow samples of enrolled patients are used for genome wide scanning by snp array. the purpose of present study is to develop predictive pharmacogenemic biomarkers model associated wit clinical outcomes including efficacy and toxicity in patients with aml with normal karyotype treated with chemotherapy using pharmacogenetic snp array. and secondly, to develop enrichment clinical trial based on predictive pharmacogenomic model.


Eligibility criteria:
inclusion criteria: * patients with normal karyotype acute myeloid leukemia * 18 years or older * patients were treated with standard chemotherapy * patients with available medical record and stored bone marrow specimen at time of diagnosis exclusion criteria: * no definitive criteria

Keywords: snp array prognosis acute myeloid leukemia normal karyotype acute myeloid leukemia with normal karyotype
acute effects of intermittent hypoxia-hyperoxia in older adults

Conditions: Older Adults; Cardiovascular Health; Blood Pressure; Sedentary

Summary: the supply of oxygen is essential for energy production, recovery from efforts, and human life. intermittent hypoxia-hyperoxia exposure (ihhe) is a novel technique in which the subject is exposed to a respiratory environment with reduced oxygen fraction, controlled through a specific software, using a facial mask and a hypoxic generation device. the objective of this study is to determine if there is a relationship between intermittent hypoxia-hyperoxia exposure and cardiorespiratory condition, blood pressure, and arterial oxygen saturation. according to our hypothesis, acute ihhe in elderly adults may influence cardiorespiratory condition, blood pressure, and arterial oxygen saturation. the study will be conducted as a randomized clinical trial. the subjects will be divided into two groups: the experimental group will undergo an ihhe session, breathing air with an oxygen concentration (fio2) ranging from 10-14% for 1-5 minutes, with 1-3 minutes of rest in hyperoxia (fio2 30-40%) for a total of 4-8 cycles, based on their acute response to hypoxia. the placebo group will undergo a 5-cycle protocol with an fio2 of 21%.


Eligibility criteria:
inclusion criteria: * being over 60 years old. * having no previous experience in hypoxic training. * engaging in less than 150 minutes of physical activity per week. exclusion criteria: * having any pathology that prevents the subject from being independent in terms of walking and functionality. * subjects with impaired cognitive abilities. * subjects with pulmonary hypertension, decompensated heart or respiratory disease. * to have or have had cancer

Keywords: hypoxic exposure older adults heart rate variability
comparison of dehydrated human amnion-chorion and type 1 bovine collagen membranes for guided bone regeneration

Conditions: Ridge Deficiency

Summary: the objective of this randomized clinical study was to evaluate the use of dehydrated human amnion-chorion membrane as an exposed barrier for guided bone regeneration (gbr) after tooth extraction and to determine whether intentional exposure of this membrane to the oral environment compromises ridge dimensions and bone vitality for implant placement.

forty-three patients requiring extraction of at least one tooth and delayed implant placement were randomly assigned to either an experimental or a control group. for both groups, demineralized freeze-dried bone allograft was used to graft the socket. for the control group, type i bovine collagen was used as a membrane; for the experimental group, human amnion-chorion membrane was used. for both groups, the barrier membranes were left exposed, and no primary closure was achieved. patients returned for implant placement after a mean healing period of 19.5 weeks, at which time a core bone biopsy specimen 2 mm in diameter was obtained for histomorphometric analyses. clinical ridge dimensions were measured at the times of extraction and implant placement.

Eligibility criteria:
inclusion criteria: . patients included in the study were required: * not to be completely edentulous. * to have at least 1 tooth that could not be saved and for which extraction and delayed implant placement were planned exclusion criteria: patients were excluded if they : * had received radiation therapy * were taking antiresorptive medication (i.e., bisphosphonate or denosumab) * had uncontrolled systemic disorders (such as uncontrolled diabetes, congestive heart failure, or acute odontogenic infections) * were smokers (more than 10 cigarettes per day) * were pregnant or breastfeeding.

Keywords: guided bone regeneration dehydrated human amnion chorion membrane type i bovine collagen membrane ridge preservation ridge healing teeth extraction
a 56-day clinical study on facial skin rejuvenation

Conditions: Skin Manifestations; Wrinkle; Photoaging

Summary: this clinical trial aims to learn about the efficacy of mlyaat-1002® (a proprietary anti-aging complex, mlyaat is short for "multi-layer anti-ageing technology" ) in female subjects who have newly received the rejuvenation treatment by comparing visual clinical scores, skin attributes measurement and image analysis.

the main expectations are: * after the 8-week continuous use of the test formulations with mlyaat-1002® on one split-face side, the clinical manifestations and scores of photoaging improve compared to those of the control side using the placebo formulations. * after the 8-week continuous use of the test formulations with mlyaat-1002®, indicators of skin tone, individual type angle (ita), cielab color space, pores and wrinkles improve compared to those of the control side using the placebo formulations.

Eligibility criteria:
inclusion criteria: * self-reported facial aging problems such as roughness, fine lines, and dull skin * no symptoms of itching, tingling, or burning on the face * no symptoms of facial flushing, erythema, papules, desquamation, or spot haemorrhage as evaluated by a dermatologist * photodamage scores above 2 (evaluated by a dermatologist) * compliance with split-face use of the assigned formulations for 56 days * no antibiotics remedy in the past three months * regular use of sunscreen products at least five times a week * no plans to leave shanghai during the period of the trial * compliance with no use of any cosmetics that may bias the study results during the period of the trial * written informed consent and portrait right consent were obtained from all participants before study entry exclusion criteria: * female subjects who are pregnant, lactating or planning to become pregnant * history of alcoholism * history of allergies * subjects who have received medical rejuvenation treatment within the past one year * being a participant in any other clinical trial within the past one month * subjects who are suffering from facial skin diseases (melasma, acne, and herpes simplex, etc.) * subjects with scar constitution or that predispose to koebner's phenomenon (such as vitiligo and lichen planus, etc.) * subjects who had skin diseases (such as psoriasis, eczema, and skin cancer, etc.) * taken/injected anti-allergy medication in the past one month * subjects who had a high fever in the past 2 weeks * received anticancer chemotherapy or immunotherapy in the past 6 months * anyone that the investigator thinks of not eligible.
doripenem in the treatment of complicated intra-abdominal infections

Conditions: Bacterial Infections and Mycoses; Appendicitis; Cholecystitis; Pancreatitis; Peritonitis

Summary: the purpose of this study is to compare the clinical response rates of doripenem versus a comparator antibiotic in treatment of hospitalized patients with complicated intra-abdominal infections.

doripenem is an antibiotic medication not yet approved by the us fda. this is a phase 3, multicenter, prospective, randomized, double-blind study of intravenous doripenem versus a comparator antibiotic to assess the effectiveness and safety of doripenem in the treatment of complicated intra-abdominal infections in hospitalized adults. the primary endpoint is the clinical response rate measured at late follow-up visit. the patients will receive either doripenem or comparator; treatment duration is 5 to 14 days.

Eligibility criteria:
inclusion criteria: * has a requirement for surgical intervention within 24 hours of study entry * requirement of antibacterial therapy in addition to surgical intervention in certain intra-abdominal infections. exclusion criteria: * female patients who are pregnant, nursing, or if of child bearing potential not using a medically accepted, effective method of birth control * any rapidly-progressing disease or immediately life-threatening illness.

Keywords: complicated intra-abdominal infections appendicitis cholecystitis peritonitis
local analgesia in knee- and hipatroplastic surgery in patients with rheumatic disease: extra- vs. intracapsulare position of catheter

Conditions: Rheumatoid Arthritis; Orthopedic Surgery; Analgesia

Summary: postoperative pain is part of surgery trauma. in orthopedic surgery artroplastic replacement of knee- and hipjoints are common. postoperative pain relieve can be complicated. a new concept for pain relieve postoperative is local infiltration analgesia (lia). this technique implicates that a catheter is left in the surgical area and that local anestesia can be administered post surgery. the goal is no or only little pain with minimal side effects. the catheter could be placed intra- or extracapsulare. the best position is not known. primary aim is to study if position of the catheter effects the need of other postoperative analgesia. secondary aim is to study if the position effects patient mobility within the first two days.


Eligibility criteria:
inclusion criteria: * patients undergoing arthroplastic surgery of knee or hip exclusion criteria: * sensitivity to local anesthetics * other reason not to use local anesthetics